Login to Your Account


Executives at Oasmia Pharmaceutical AB came to the J.P. Morgan Healthcare Conference (JPM) recently confident they had every chance of perking up investor interest in their story.

What are the chances that two guys with the same name but no family connection would co-found a company? The odds seem especially slim when the name isn’t just Smith or Jones but Radin – Andrew A., the CEO, and Andrew M., the chief business officer, to be exact.

LONDON – U.K. newco Centauri Therapeutics Ltd. has acquired the alphamer anti-infective technology inspired by Nobel Laureate and inventor of the polymerase chain reaction Kary Mullis, and raised £3 million (US$4.3 million) to complete preclinical development of the lead compound.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: